← MiniMed Group, Inc. Common Stock overview

MiniMed Group, Inc. Common Stock vs DexCom: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

MiniMed Group, Inc. Common Stock (MMED)

Q3 2026
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

July 2026
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

Latest
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

DexCom Inc (DXCM)

Q3 2026
▲3▼1

DexCom gains on FDA clearance, strong Q2, and expanded coverage

  • FDA clears Stelo for young children The FDA cleared DexCom's Stelo biosensor for children aged 2 and up, opening a new market and supporting the stock.

    This is a new regulatory win that expands the addressable market.

  • Q2 revenue up 13%, guidance raised Q2 revenue rose 13% to $1.31 billion, leading DexCom to raise its 2026 revenue and margin guidance, a sign of strong business momentum.

    This is a new financial update that directly boosts investor confidence.

  • Investor Day and G7 rollout lift shares DexCom's Investor Day sent shares up 25%, and the G7 15 Day rollout progressed, with major PBM coverage now reaching over 7 million non-insulin Type 2 patients.

    These are new events that drove the stock higher during the quarter.

  • Abbott competition intensifies Abbott's FreeStyle Libre topped $2 billion in Q2 sales, and the FDA approved Abbott's Libre Duo, the first U.S. wearable tracking both glucose and ketones, potentially pressuring DexCom's pricing and market share.

    This is a new competitive threat that could weigh on DexCom's future growth.

August 2026
▲3▼1

DexCom's Strong Q2 and G7 Rollout Drive Gains, but Abbott Competition Looms

  • Q2 Beat and Raised 2026 Outlook DexCom reported Q2 revenue up 13% to $1.31 billion and raised its full-year revenue and margin guidance, citing manufacturing efficiencies and the G7 15 Day sensor. This directly boosts investor confidence in future profits, pushing the stock up.

    This is the core fundamental news that explains the stock's recent strength and improved outlook.

  • G7 15 Day Rollout and Reimbursement Progress DexCom is on track to convert nearly half of its U.S. customers to the G7 15 Day system by year-end, with coverage from the four largest PBMs covering over 7 million non-insulin Type 2 patients. This expands the market and supports long-term growth.

    It shows a concrete driver of future revenue and margin expansion, which is key to the bull case.

  • Abbott's New Dual Ketone-Glucose Wearable Approved The FDA approved Abbott's Libre Duo 10 Day, the first U.S. wearable to continuously track both glucose and ketones. This could make Abbott's product more attractive and intensify competition, potentially pressuring DexCom's market share and pricing.

    It introduces a new competitive threat that could cap DexCom's upside and is a real counterweight to the positive news.

  • Analyst Upgrades and Fair Value Increase Several analysts raised their price targets to $88–$96, lifting DexCom's fair value estimate to $91.64, after strong Q2 results and margin upside. This reflects growing optimism and can attract more investors, supporting the stock price.

    It shows external validation of the company's improved prospects, which influences investor sentiment and demand for the stock.

Latest
▲3▼1

DexCom's Strong Q2 and G7 Rollout Drive Gains, but Abbott Competition Looms

  • Q2 Beat and Raised 2026 Outlook DexCom reported Q2 revenue up 13% to $1.31 billion and raised its full-year revenue and margin guidance, citing manufacturing efficiencies and the G7 15 Day sensor. This directly boosts investor confidence in future profits, pushing the stock up.

    This is the core fundamental news that explains the stock's recent strength and improved outlook.

  • G7 15 Day Rollout and Reimbursement Progress DexCom is on track to convert nearly half of its U.S. customers to the G7 15 Day system by year-end, with coverage from the four largest PBMs covering over 7 million non-insulin Type 2 patients. This expands the market and supports long-term growth.

    It shows a concrete driver of future revenue and margin expansion, which is key to the bull case.

  • Abbott's New Dual Ketone-Glucose Wearable Approved The FDA approved Abbott's Libre Duo 10 Day, the first U.S. wearable to continuously track both glucose and ketones. This could make Abbott's product more attractive and intensify competition, potentially pressuring DexCom's market share and pricing.

    It introduces a new competitive threat that could cap DexCom's upside and is a real counterweight to the positive news.

  • Analyst Upgrades and Fair Value Increase Several analysts raised their price targets to $88–$96, lifting DexCom's fair value estimate to $91.64, after strong Q2 results and margin upside. This reflects growing optimism and can attract more investors, supporting the stock price.

    It shows external validation of the company's improved prospects, which influences investor sentiment and demand for the stock.

July 2026
▲3▼1

DexCom's growth story gets FDA boost, raised guidance, but Abbott competition looms

  • FDA clears Stelo for kids, expanding market DexCom won FDA clearance for its Stelo glucose biosensor in children aged 2 and older who don't use insulin, opening a new patient group. This expands the potential customer base and supports future sales growth, which can lift the stock as investors see a bigger runway.

    This is a new regulatory win that directly expands DexCom's addressable market and is a key positive catalyst.

  • DexCom raises 2026 revenue outlook after strong Q2 DexCom reported Q2 revenue of $1.31 billion, up 13%, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion. It also lifted margin guidance. This shows the business is growing faster than expected, which typically pushes the stock up.

    This is a fresh earnings report with raised guidance, a major positive driver for the stock.

  • Abbott's CGM growth and new sensor intensify competition Abbott's FreeStyle Libre CGM sales topped $2 billion in Q2 and grew 9.5%, and it won CE Mark for a new dual glucose-ketone sensor. Abbott's expansion into the large Type 2 market could pressure DexCom's pricing and market share, a real headwind.

    This highlights the main competitive threat that could cap DexCom's upside and is a recurring negative theme.

  • Investor Day reassures on long-term growth DexCom's management presented robust growth targets through 2030 at its Investor Day, helping drive a 25% share price increase. The event shifted sentiment positively as investors gained confidence in the long-term pipeline and market penetration potential.

    This explains a major positive sentiment shift and is a new event that boosted the stock.

▲3▼1

DexCom's growth story gets FDA boost, raised guidance, but Abbott competition looms

  • FDA clears Stelo for kids, expanding market DexCom won FDA clearance for its Stelo glucose biosensor in children aged 2 and older who don't use insulin, opening a new patient group. This expands the potential customer base and supports future sales growth, which can lift the stock as investors see a bigger runway.

    This is a new regulatory win that directly expands DexCom's addressable market and is a key positive catalyst.

  • DexCom raises 2026 revenue outlook after strong Q2 DexCom reported Q2 revenue of $1.31 billion, up 13%, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion. It also lifted margin guidance. This shows the business is growing faster than expected, which typically pushes the stock up.

    This is a fresh earnings report with raised guidance, a major positive driver for the stock.

  • Abbott's CGM growth and new sensor intensify competition Abbott's FreeStyle Libre CGM sales topped $2 billion in Q2 and grew 9.5%, and it won CE Mark for a new dual glucose-ketone sensor. Abbott's expansion into the large Type 2 market could pressure DexCom's pricing and market share, a real headwind.

    This highlights the main competitive threat that could cap DexCom's upside and is a recurring negative theme.

  • Investor Day reassures on long-term growth DexCom's management presented robust growth targets through 2030 at its Investor Day, helping drive a 25% share price increase. The event shifted sentiment positively as investors gained confidence in the long-term pipeline and market penetration potential.

    This explains a major positive sentiment shift and is a new event that boosted the stock.

© 2026 MarketIVWhy